HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NRXS

Neuraxis Inc

Last Close
Feb 13  •  04:00PM ET
4.91
Dollar change
+0.06
Percentage change
1.24 %
Healthcare • Biotechnology • USA • AMEX
Peers: MDT BSX ABT SYK ISRG ZBH RMD EW ALGN BIO
Index- P/E- EPS (ttm)-1.02 Insider Own28.48% Shs Outstand9.89M Perf Week12.87%
Market Cap52.31M Forward P/E- EPS next Y-0.56 Insider Trans13.72% Shs Float7.62M Perf Month3.59%
Enterprise Value48.41M PEG- EPS next Q-0.21 Inst Own15.04% Short Float1.46% Perf Quarter88.85%
Income-8.33M P/S15.57 EPS this Y16.67% Inst Trans9.56% Short Ratio0.32 Perf Half Y107.17%
Sales3.36M P/B21.28 EPS next Y44.50% ROA-217.92% Short Interest0.11M Perf YTD8.15%
Book/sh0.23 P/C11.94 EPS next 5Y51.14% ROE-3071.15% 52W High6.20 -20.81% Perf Year103.73%
Cash/sh0.41 P/FCF- EPS past 3/5Y-25.70% -14.82% ROIC-332.39% 52W Low1.33 269.17% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y-0.44% 8.61% Gross Margin84.34% Volatility10.60% 7.85% Perf 5Y-
Dividend TTM- EV/Sales14.41 EPS Y/Y TTM43.58% Oper. Margin-225.43% ATR (14)0.37 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.55 Sales Y/Y TTM36.89% Profit Margin-247.63% RSI (14)62.83 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.58 EPS Q/Q6.37% SMA207.35% Beta2.63 Target Price7.00
Payout- Debt/Eq0.21 Sales Q/Q21.72% SMA5021.30% Rel Volume0.27 Prev Close4.85
Employees21 LT Debt/Eq0.10 EarningsNov 11 BMO SMA20063.99% Avg Volume352.21K Price4.91
IPOAug 09, 2023 Option/ShortNo / Yes EPS/Sales Surpr.-20.00% -18.86% Trades Volume94,023 Change1.24%
Jan-08-26 08:00AM
NeurAxis Achieves Major Milestone with AMA Category I CPT Code Now in Effect, Establishing a Permanent Reimbursement Pathway
(GlobeNewswire)
Jan-06-26 04:41AM
The Zacks Analyst Blog Meta, Bank of America, The Procter & Gamble, Espey and NeurAxis
(Zacks)
Jan-05-26 04:34PM
Top Stock Reports for Meta, Bank of America & Procter & Gamble
(Zacks)
Dec-19-25 08:00AM
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
(GlobeNewswire) +11.81%
Dec-01-25 07:00AM
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
(GlobeNewswire)
12:17PM Loading…
Nov-17-25 12:17PM
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
(Zacks)
Nov-12-25 08:00AM
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
(GlobeNewswire) +7.88%
Nov-11-25 07:00AM
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
(GlobeNewswire) -5.86%
Nov-04-25 08:30AM
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
(GlobeNewswire) -5.22%
Oct-24-25 08:00AM
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
(GlobeNewswire) -8.64%
Sep-18-25 08:00AM
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
(GlobeNewswire)
Sep-17-25 05:53AM
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis
(Zacks) +5.35%
Sep-16-25 04:42PM
Top Research Reports for Alphabet, IBM & Merck
(Zacks)
Aug-18-25 02:27PM
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
(Zacks)
Aug-12-25 07:00AM
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
(GlobeNewswire)
08:30AM Loading…
Aug-05-25 08:30AM
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
(GlobeNewswire)
Jun-27-25 04:53AM
The Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technologies and NeurAxis
(Zacks)
Jun-26-25 04:34PM
Top Stock Reports for Microsoft, NVIDIA & Bank of America
(Zacks)
Jun-17-25 08:00AM
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
(GlobeNewswire)
Jun-10-25 08:00AM
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
(GlobeNewswire) -8.65%
May-27-25 08:00AM
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
(GlobeNewswire)
May-22-25 01:03PM
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
(GlobeNewswire) -5.31%
May-21-25 07:00AM
NeurAxis Announces $5.0 Million Registered Direct Offering
(GlobeNewswire) -19.80%
May-20-25 08:00AM
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
(GlobeNewswire) +75.77%
May-15-25 12:06PM
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones
(Zacks)
May-12-25 08:15AM
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
(GlobeNewswire) +16.00%
May-05-25 09:00AM
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
(GlobeNewswire) -11.64%
May-01-25 04:49AM
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis
(Zacks)
Apr-30-25 05:02PM
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems
(Zacks) +5.86%
Apr-15-25 09:00AM
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025
(GlobeNewswire)
11:20AM Loading…
Mar-24-25 11:20AM
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
(Zacks) -6.06%
Mar-20-25 04:18PM
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
(SeekingAlpha)
08:15AM
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
(GlobeNewswire)
Mar-12-25 09:00AM
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
(GlobeNewswire)
Jan-21-25 01:45PM
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
(GlobeNewswire)
09:00AM
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
(GlobeNewswire)
Jan-13-25 09:00AM
NeurAxis Inc. Issues Letter to Shareholders
(GlobeNewswire)
Jan-08-25 09:00AM
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
(GlobeNewswire)
Jan-06-25 09:00AM
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
(GlobeNewswire) +11.57%
Dec-10-24 09:00AM
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
(GlobeNewswire) -7.48%
Nov-12-24 08:10AM
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
(GlobeNewswire) +26.40%
Nov-05-24 09:00AM
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
(GlobeNewswire)
Nov-04-24 09:00AM
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
(GlobeNewswire)
Oct-29-24 09:00AM
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024
(GlobeNewswire)
Oct-22-24 09:00AM
NeurAxis Announces New CPT Category I Code for Percutaneous Electrical Nerve Field Stimulation
(GlobeNewswire) +5.07%
Sep-19-24 09:00AM
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
(GlobeNewswire)
Aug-27-24 09:00AM
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
(GlobeNewswire)
Aug-13-24 09:00AM
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
(GlobeNewswire)
Aug-09-24 08:00AM
NeurAxis Reports Second Quarter 2024 Financial Results
(GlobeNewswire) +9.12%
Aug-05-24 09:00AM
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
(GlobeNewswire) -17.61%
Jun-07-24 09:00AM
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
(GlobeNewswire)
May-22-24 08:00AM
NeurAxis Reports First Quarter 2024 Financial Results
(GlobeNewswire)
May-21-24 09:00AM
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
(GlobeNewswire)
May-16-24 09:00AM
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
(GlobeNewswire) +11.96%
May-15-24 04:30PM
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
(GlobeNewswire)
Apr-23-24 09:00AM
NeurAxis Announces New Medical Policy Coverage in North Dakota
(GlobeNewswire) -11.18%
Apr-12-24 08:44AM
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Apr-09-24 04:05PM
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
(GlobeNewswire)
Apr-01-24 04:15PM
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
(GlobeNewswire)
Mar-27-24 09:00AM
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
(GlobeNewswire)
Mar-11-24 09:00AM
NeurAxis Announces Highmark BCBS Policy Coverage
(GlobeNewswire)
Mar-04-24 09:00AM
NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
(GlobeNewswire) +8.82%
Feb-27-24 11:00AM
NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
(GlobeNewswire)
Jan-31-24 09:00AM
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
(GlobeNewswire)
Dec-20-23 09:00AM
NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
(GlobeNewswire)
Nov-20-23 05:30PM
NeurAxis Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Nov-15-23 09:00AM
NeurAxis Announces CareFirst BCBS Policy Coverage
(GlobeNewswire) +14.17%
Nov-14-23 09:00AM
NeurAxis Secures $3 Million Financing
(GlobeNewswire)
Nov-08-23 09:00AM
NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
(GlobeNewswire)
Sep-26-23 09:00AM
NeurAxis Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders
(GlobeNewswire)
Sep-21-23 08:00AM
NeurAxis Reports Second Quarter 2023 Financial Results
(GlobeNewswire)
Sep-13-23 09:00AM
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
(GlobeNewswire) +7.87%
Sep-12-23 10:15AM
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
(Benzinga) -16.92%
09:00AM
NeurAxis Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS
(GlobeNewswire)
Aug-29-23 09:00AM
NeurAxis Highlights Pediatric Post-Concussion Clinical Study
(GlobeNewswire)
Aug-24-23 09:00AM
NeurAxis Highlights Strength of its Board of Directors
(GlobeNewswire) -10.15%
Aug-22-23 09:00AM
NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome
(GlobeNewswire) +16.50%
Aug-17-23 09:02AM
NeurAxis Announces Over $8 Million in IB-Stim Revenue
(GlobeNewswire)
Aug-15-23 09:00AM
NeurAxis Announces Positive University of Michigan IB-Stim Cost Effectiveness Study at ANMS 2023
(GlobeNewswire)
Aug-11-23 09:30AM
Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.
(ACCESSWIRE)
Aug-10-23 09:00AM
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
(GlobeNewswire)
09:00AM
Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing
(GlobeNewswire)
Aug-09-23 10:00AM
NeurAxis Announces Pricing of Initial Public Offering
(GlobeNewswire)
NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. Its product, IB-Stim, is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hannasch Brian10% OwnerFeb 12 '26Buy4.9240,000196,8001,211,522Feb 13 04:04 PM
Hannasch Brian10% OwnerFeb 11 '26Buy4.6540,000186,0001,171,522Feb 13 04:04 PM
Aharon GilDirectorDec 23 '25Buy3.52286,1381,007,206286,138Dec 29 05:12 PM
MASIMO CORP10% OwnerJul 01 '25Sale2.25821,3271,847,9860Jul 03 05:38 PM
Hannasch Brian10% OwnerJul 01 '25Buy2.25355,556800,0011,131,522Jul 03 11:24 AM
Hannasch Brian10% OwnerApr 21 '25Buy1.7318,06531,251775,966Apr 23 04:38 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

DCTH

Delcath Systems Inc

Last Close
Feb 13  •  04:00PM ET
9.31
Dollar change
+0.19
Percentage change
2.08 %
Healthcare • Medical Devices • USA • NASD
DCTH Delcath Systems Inc daily Stock Chart
Peers: MNOV CRMD BLRX PSTV HOOK CYCN AVGR SCPH TTOO
 | Held by: VTI IWM VXF SURI IWO VTWO IWC GSSC ITOT SBIO
IndexRUT P/E1082.56 EPS (ttm)0.01 Insider Own4.42% Shs Outstand35.31M Perf Week-0.64%
Market Cap328.77M Forward P/E59.07 EPS next Y0.16 Insider Trans1.03% Shs Float33.75M Perf Month-10.31%
Enterprise Value240.82M PEG- EPS next Q-0.06 Inst Own52.06% Short Float12.47% Perf Quarter8.38%
Income1.20M P/S4.13 EPS this Y105.12% Inst Trans-0.89% Short Ratio7.19 Perf Half Y-11.08%
Sales79.60M P/B2.86 EPS next Y231.00% ROA1.54% Short Interest4.21M Perf YTD-7.82%
Book/sh3.25 P/C3.70 EPS next 5Y- ROE1.94% 52W High18.23 -48.93% Perf Year-42.81%
Cash/sh2.52 P/FCF27.31 EPS past 3/5Y36.35% 69.36% ROIC1.04% 52W Low8.12 14.66% Perf 3Y89.23%
Dividend Est.- EV/EBITDA38.90 Sales past 3/5Y118.74% 88.10% Gross Margin86.29% Volatility6.76% 5.15% Perf 5Y-57.02%
Dividend TTM- EV/Sales3.03 EPS Y/Y TTM101.70% Oper. Margin7.39% ATR (14)0.50 Perf 10Y-100.00%
Dividend Ex-Date- Quick Ratio13.71 Sales Y/Y TTM251.54% Profit Margin1.50% RSI (14)42.17 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio15.06 EPS Q/Q-64.06% SMA20-6.36% Beta0.37 Target Price23.29
Payout- Debt/Eq0.01 Sales Q/Q83.60% SMA50-7.43% Rel Volume0.51 Prev Close9.12
Employees96 LT Debt/Eq0.01 EarningsNov 04 BMO SMA200-18.52% Avg Volume585.53K Price9.31
IPOOct 23, 2001 Option/ShortYes / Yes EPS/Sales Surpr.640.54% 0.32% Trades Volume295,948 Change2.08%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Craig Hallum Buy $18
May-14-24Initiated Stephens Overweight $25
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Feb-12-26 08:00AM
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
(Business Wire)
Feb-11-26 03:15PM
Clear Street Raises Delcath Systems, Inc. (DCTH) Target to $29, Maintains Buy Rating
(Insider Monkey) -5.94%
Jan-27-26 08:05AM
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
(Business Wire)
Jan-21-26 04:01PM
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +6.19%
Jan-09-26 08:05AM
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
(Business Wire)
08:38AM Loading…
Jan-02-26 08:38AM
Are Options Traders Betting on a Big Move in Delcath Systems Stock?
(Zacks)
Jan-01-26 08:15AM
Delcath Systems publishes results from subgroup analyses of FOCUS study
(TipRanks)
Dec-31-25 08:00AM
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
(Business Wire)
Dec-16-25 10:25AM
Here's What Hit Delcath Systems (DCTH) in Q3
(Insider Monkey)
Dec-03-25 04:01PM
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
(Business Wire)
Nov-24-25 08:36AM
Do Options Traders Know Something About Delcath Systems Stock We Don't?
(Zacks)
Nov-20-25 04:01PM
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
(Business Wire) +9.40%
Nov-18-25 08:00AM
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
(Business Wire)
05:07AM
H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT
(Insider Monkey)
Nov-14-25 04:01PM
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
08:30AM Loading…
Nov-13-25 08:30AM
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
(Business Wire)
Nov-06-25 04:01PM
Delcath Systems to Participate in Upcoming Investor Conferences
(Business Wire)
Nov-04-25 04:06PM
Delcath Systems Inc (DCTH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
09:15AM
Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
(Zacks)
08:00AM
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
(Business Wire)
Oct-27-25 04:43PM
Short Sellers Are Targeting Small-Caps. Megacaps Are Getting a Pass.
(Barrons.com)
Oct-21-25 08:30AM
Delcath Systems to Host Third Quarter 2025 Earnings Call
(Business Wire)
Oct-18-25 04:15PM
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
(Business Wire)
04:13PM
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
(Business Wire)
Sep-22-25 04:01PM
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
(Business Wire)
Sep-05-25 04:01PM
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-04-25 02:52PM
Invesco Backs Delcath Systems (DCTH) on Expansion Potential
(Insider Monkey)
Aug-21-25 08:30AM
Delcath Systems to Participate in Upcoming Investor Conferences
(Business Wire)
Aug-19-25 08:30AM
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
(Business Wire)
Aug-13-25 12:08PM
H.C. Wainwright Remains Bullish on Delcath Systems (DCTH)
(Insider Monkey)
09:15AM Loading…
Aug-06-25 09:15AM
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates
(Zacks)
08:00AM
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
(Business Wire)
Jul-29-25 04:01PM
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
(Business Wire)
Jul-28-25 05:15PM
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
Jul-25-25 04:01PM
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jul-23-25 04:01PM
Delcath Systems to Host Second Quarter 2025 Earnings Call
(Business Wire)
Jul-17-25 08:32AM
Is the Options Market Predicting a Spike in Delcath Systems Stock?
(Zacks)
Jun-04-25 12:00PM
Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know
(Zacks)
09:40AM
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?
(Zacks)
May-28-25 09:55AM
Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's What You Should Know
(Zacks)
08:50AM
Here's Why Momentum in Delcath Systems (DCTH) Should Keep going
(Zacks)
May-22-25 07:00AM
Delcath Systems Issues Full Year 2025 Guidance
(Business Wire) -6.32%
May-15-25 04:30PM
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
(Business Wire) +6.54%
May-09-25 05:30PM
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
03:15AM
Delcath Systems Inc (DCTH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
May-08-25 08:45AM
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates
(Zacks) +23.64%
07:30AM
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
(Business Wire)
May-07-25 06:00PM
Here are the major earnings before the open tomorrow
(Seeking Alpha)
02:21PM
Delcath Systems Q1 2025 Earnings Preview
(Seeking Alpha)
May-06-25 07:10AM
Waters (WAT) Q1 Earnings and Revenues Beat Estimates
(Zacks)
Apr-28-25 08:30AM
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer
(Business Wire)
Apr-27-25 09:22AM
Immunocore Holdings: A Name On My Watch List
(Seeking Alpha)
Apr-24-25 04:01PM
Delcath Systems to Host First Quarter 2025 Earnings Call
(Business Wire)
Apr-10-25 09:03AM
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock?
(Zacks) -7.71%
Apr-09-25 05:00PM
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
(Business Wire) +9.82%
Apr-02-25 11:49AM
Hospitals Experience FOMO In Adopting Delcath's PHP Treatment
(Seeking Alpha)
Mar-27-25 04:45PM
Beta Bionics Announces Board Appointment of Gerard Michel
(GlobeNewswire)
10:46AM
Jim Cramer Blesses Delcath Systems (DCTH): 'You're Not Early, But It's a Win'
(InsiderMonkey)
Mar-26-25 09:55AM
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High?
(Zacks) -6.52%
Mar-24-25 04:01PM
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
(Business Wire)
Mar-19-25 09:40AM
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
(Zacks)
Mar-14-25 04:01PM
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-06-25 08:00AM
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
(Business Wire)
Feb-20-25 08:30AM
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
(Business Wire)
Feb-14-25 08:30AM
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
(Business Wire)
Jan-31-25 07:00AM
Biotech walks a 'tightrope' amid unclear funding, regulations
(Yahoo Finance Video)
Jan-28-25 04:01PM
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
(Business Wire)
Jan-15-25 02:31PM
Delcath Systems, Inc. (DCTH): Analysts Recommend This 52-Week High Stocks Now
(Insider Monkey)
Jan-13-25 08:00AM
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
(Business Wire) +11.41%
Jan-03-25 04:01PM
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Dec-30-24 08:00AM
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
(Business Wire)
Dec-02-24 08:30AM
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
(Business Wire) +6.40%
Nov-09-24 04:00PM
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Nov-08-24 08:00AM
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
(Business Wire)
Nov-01-24 04:01PM
Delcath Systems to Participate in Upcoming Investor Conferences
(Business Wire)
Oct-25-24 08:30AM
Delcath Systems to Host Third Quarter 2024 Earnings Call
(Business Wire)
Oct-17-24 08:30AM
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
(Business Wire) +7.57%
Sep-20-24 04:01PM
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-16-24 08:30AM
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT in Metastatic Uveal Melanoma Subgroups
(Business Wire)
Aug-28-24 04:01PM
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
(Business Wire)
04:01PM
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
(Business Wire)
Aug-27-24 08:30AM
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
(Business Wire) +15.57%
Aug-26-24 04:01PM
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
(Business Wire) +13.86%
Aug-20-24 08:30AM
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
(Business Wire)
Aug-12-24 04:01PM
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Aug-05-24 08:59PM
DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024
(InvestorPlace)
04:01PM
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
(Business Wire)
08:30AM
Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT
(Business Wire)
Jul-30-24 04:01PM
Delcath Systems to Participate in Upcoming Investor Conferences
(Business Wire)
Jul-22-24 04:01PM
Delcath Systems to Host Second Quarter 2024 Earnings Call
(Business Wire)
Jul-15-24 12:00PM
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
(Zacks)
Jun-14-24 08:50AM
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength
(Zacks)
Jun-03-24 09:55AM
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?
(Zacks)
May-28-24 09:30AM
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
(Business Wire) -5.53%
May-17-24 09:55AM
Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know
(Zacks) +8.76%
May-15-24 08:50AM
What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'
(Zacks)
03:02AM
Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
(GuruFocus.com)
May-14-24 11:52AM
DCTH Stock Earnings: Delcath Systems Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace) +30.93%
07:30AM
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
(PR Newswire)
May-07-24 08:30AM
Delcath Systems to Host First Quarter 2024 Earnings Call
(PR Newswire)
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sylvester John RichardDirectorNov 21 '25Buy8.894,38638,99214,936Nov 25 04:15 PM
MICHEL GERARD JCHIEF EXECUTIVE OFFICERNov 11 '25Buy8.5311,50098,049330,834Nov 13 11:53 AM
Vukovic VojoCHIEF MEDICAL OFFICERJun 12 '25Option Exercise4.7842,000200,760168,882Jun 13 05:22 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.